2seventy bioTSVT
TSVT
About: 2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment focusing on researching, developing and commercializing potentially transformative treatments for cancer.
Employees: 65
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
418% more call options, than puts
Call options by funds: $57K | Put options by funds: $11K
31% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 16
31% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 26
1.67% more ownership
Funds ownership: 87.41% [Q3] → 89.07% (+1.67%) [Q4]
1% more funds holding
Funds holding: 113 [Q3] → 114 (+1) [Q4]
36% less capital invested
Capital invested by funds: $213M [Q3] → $135M (-$77.6M) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
0%
upside
Avg. target
$5
0%
upside
High target
$5
0%
upside
2 analyst ratings
0 positive
0%
2 neutral
100%
0 negative
0%
Morgan Stanley Matthew Harrison 38% 1-year accuracy 9 / 24 met price target | 0%upside $5 | Equal-Weight Maintained | 14 Mar 2025 |
Leerink Partners Daina Graybosch 0% 1-year accuracy 0 / 1 met price target | 0%upside $5 | Market Perform Downgraded | 11 Mar 2025 |
Financial journalist opinion
Neutral
Business Wire
3 days ago
2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of 2seventy bio, Inc. (NasdaqGS: TSVT) to Bristol Myers Squibb (NYSE: BMY). Under the terms of the proposed transaction, shareholders of 2seventy will receive $5.00 in cash for each share of 2seventy that they own. KSF is seeking to determine whether this consideration and the process that led to it ar.
Neutral
Business Wire
3 weeks ago
2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights for the fourth quarter and full year ended December 31, 2024. “2024 was a pivotal year for 2seventy as we made significant changes to our business to streamline cost structure and focus solely on Abecma,” said Chip Baird, chief executive officer, 2seventy bio. “This week marks four years since Abecma received FDA approval as the first anti-BCMA CAR T cell therapy approved.
Positive
Zacks Investment Research
1 month ago
2seventy bio, Inc. (TSVT) Upgraded to Buy: Here's Why
2seventy bio, Inc. (TSVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
Business Wire
1 month ago
2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of 2seventy bio, Inc. (NasdaqGS: TSVT) to Bristol Myers Squibb (NYSE: BMY). Under the terms of the proposed transaction, shareholders of 2seventy will receive $5.00 in cash for each share of 2seventy that they own. KSF is seeking to determine whether this consideration and the process that led to.
Neutral
PRNewsWire
1 month ago
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of 2seventy bio, Inc. - TSVT
NEW YORK , March 12, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating 2seventy bio, Inc. (NASDAQ: TSVT ), relating to the proposed merger with Bristol Myers Squibb.
Neutral
Business Wire
1 month ago
Shareholder Alert: The Ademi Firm investigates whether 2seventy bio, Inc. is obtaining a Fair Price for its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating 2seventy bio (Nasdaq: TSVT) for possible breaches of fiduciary duty and other violations of law in its transaction with Bristol Myers Squibb. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, 2seventy bio shareolders will receive only $5.00 per share in an all-cash transaction for.
Positive
Zacks Investment Research
1 month ago
TSVT Up on Acquisition Agreement With BMY for $286 Million
2seventy bio agrees to be acquired by partner BMY for $286 million. Shares gain.
Neutral
PRNewsWire
1 month ago
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.
NEW YORK , March 11, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by 2seventy bio, Inc. (NASDAQ: TSVT) and its board of directors concerning the proposed acquisition of the company by Bristol Myers Squibb (NYSE: BMY). Stockholders will receive $5.00 for each share of 2seventy bio stock that they hold.
Positive
Benzinga
1 month ago
Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal
On Monday, Bristol Myers Squibb & Co BMY agreed to acquire 2seventy bio, Inc. TSVT at $5.00 per share in an all-cash transaction for a total equity value of approximately $286 million, or $102 million net of estimated cash.
Negative
Benzinga
1 month ago
Top 3 Health Care Stocks That May Keep You Up At Night In Q1
As of March 11, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Charts implemented using Lightweight Charts™